Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) EBITDA (2020 - 2025)

Bioventus' EBITDA history spans 6 years, with the latest figure at $19.4 million for Q4 2025.

  • For Q4 2025, EBITDA rose 228.08% year-over-year to $19.4 million; the TTM value through Dec 2025 reached $27.5 million, up 146.03%, while the annual FY2025 figure was $28.1 million, 154.87% up from the prior year.
  • EBITDA reached $19.4 million in Q4 2025 per BVS's latest filing, up from $2.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $23.8 million in Q2 2021 to a low of -$138.6 million in Q2 2023.
  • Average EBITDA over 5 years is -$18.8 million, with a median of -$5.0 million recorded in 2024.
  • Peak YoY movement for EBITDA: tumbled 3848.29% in 2022, then soared 228.08% in 2025.
  • A 5-year view of EBITDA shows it stood at -$1.9 million in 2021, then crashed by 3848.29% to -$76.0 million in 2022, then surged by 41.0% to -$44.9 million in 2023, then soared by 66.25% to -$15.1 million in 2024, then skyrocketed by 228.08% to $19.4 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's EBITDA are $19.4 million (Q4 2025), $2.1 million (Q3 2025), and $8.7 million (Q2 2025).